Clinical and demographic factors associated with receipt of non guideline-concordant initial therapy for nonmetastatic prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 39, Issue 1, 2016, Pages 55-63

  Hamilton, Ann S ^a   Fleming, Steven T ^b   Wang, Dian ^c   Goodman, Michael ^d   Wu, Xiao Cheng ^e   Owen, Jean B ^f   Lo, Mary ^a   Ho, Alex ^f   Anderson, Roger T ^g   Thompson, Trevor ^h  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d EMORY UNIVERSITY   (United States)

^e LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f General Clinical Research Center   (United States)

^g PENN STATE COLLEGE OF MEDICINE   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cancer registry; Guideline care; Initial therapy; Prostate cancer

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; COMORBIDITY; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK POPULATION; HUMAN; MALE; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATECTOMY; RURAL POPULATION; SINGLE MAN; AGE; BRACHYTHERAPY; CAUCASIAN; ETHNOLOGY; HEALTH INSURANCE; MARRIAGE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATIC NEOPLASMS; PROTOCOL COMPLIANCE; RADIOTHERAPY; REGISTER; RISK FACTOR; STATISTICS AND NUMERICAL DATA; URBAN POPULATION; UTILIZATION; WATCHFUL WAITING;

ANTIANDROGEN;

AFRICAN AMERICANS; AGE FACTORS; AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; GUIDELINE ADHERENCE; HUMANS; INSURANCE, HEALTH; MALE; MARITAL STATUS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINES AS TOPIC; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; REGISTRIES; RISK FACTORS; RURAL POPULATION; URBAN POPULATION; WATCHFUL WAITING;

EID: 84957841263     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000017     Document Type: Article

References (27)

1. Scherr D, Swindle PW, Scardino PT, National Comprehensive Cancer Network. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology. 2003; 61(suppl 1):14-24.
2. Penson DF, Litwin MS. Quality of life after treatment for prostate cancer. Curr Urol Rep. 2003;4:185-195.
3. Brawley O. Nonmedical factors in treatment selection. Urol Clin North Am. 2003;30:331-335.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, Version 1.2002: PROS-1, 2002.
5. National Comprehensive Cancer Network (NCCN). National Comprehensive Cancer Network Prostate Cancer practice guidelines in oncology, Version 2.2005, 2006.
6. Hewitt M, Simone J. Enhancing Data Systems to Improve the Quality of Cancer Care. Washington, DC: National Academy Press; 2000.
7. IOM (Institute of Medicine). Initial National Priorities for Comparative Effectiveness Research. Washington, DC: National Academies Press; 2009.
8. German R, Wike J, Bauer K, et al. Quality of cancer registry data: findings from CDC-NPCR's Breast and Prostate Cancer Data Quality and Patterns of Care Study. J Registry Manag. 2011; 38:75-86.
9. Howlader N, Ries LA, Stinchcomb DG, et al. The impact of underreported veterans affairs data on national cancer statistics: analysis using population-based SEER registries. J Natl Cancer Inst. 2009;101:533-536.
10. Piccirillo J, Creech C, Zequeira R, et al. Inclusion of comorbidity into oncology data registries. J Registry Manag. 1999;26:66-70.
11. Johnson A, Piccirillo J, Creech C, et al. Validation of a comorbidity education program. J Registry Manag. 2001;28:125-131.
12. Piccirillo J, Costas I, Claybour P, et al. The measurement of comorbidity by cancer registries. J Registry Manag. 2003;30:8-14.
13. Piccirillo J, Tierney R, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2006;291: 2441-2447.
14. Arias E. United States Life Tables, 2004. National Vital Statistics Reports, Vol 56, No. 9, Hyattsville, MD, National Center for Health Statistics, 2007:2016-2017, 2022-2023.
15. Byers T, Wolf H, Bauer K, et al. The impact of socioeconomic status on survival after cancer in the United States. Cancer. 2008; 113:585-591.
16. Crawford ED. Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks. Urology. 2003;62(suppl 1): 13-19.
17. Daskivich T, Fan K-H, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a US population-based cohort of men with prostate cancer. Ann Intern Med. 2013;158:709-717.
18. Putt M, Long JA, Montagnet C, et al. Racial differences in the impact of comorbidities on survival among elderly men with prostate cancer. Med Care Res Rev. 2009;66:409-435.
19. Wong Y-N, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683-2693.
20. Resnick M, Koyama T, Fan K-H, et al. Long term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436-445.
21. Hoffman R, Koyama T, Fan K-H, et al. Mortality following radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst. 2013;105:711-718.
22. Hamilton A, Albertsen P, Johnson T, et al. Trends in treatment of localized prostate cancer using supplemented cancer registry data. Br J Urol Int. 2011;107:576-584.
23. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8:162-200.
24. Walz J, Suardi N, Shariat SF, et al. Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU Int. 2008;102:33-38.
25. Krahn MD, Bremner KE, Asaria J, et al. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology. 2002;60: 258-263.
26. Fleming S, Hamilton A, Sabatino S, et al. Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review. Med Care. 2012. [Epub ahead of print]. doi: 10.1097/MLR.0b013e318277eba5.
27. Hamilton A, Wu X-C, Lipscomb J, et al. Regional, provider, and economic factors associated with the choice of active surveillance in the treatment of men with localized prostate cancer. J Natl Cancer Inst Monogr. 2012;45:213-220.